Atara Biotherapeutics Inc (NASDAQ:ATRA) CEO Isaac E. Ciechanover sold 20,000 shares of the business’s stock in a transaction dated Wednesday, February 14th. The shares were sold at an average price of $46.80, for a total value of $936,000.00. Following the completion of the transaction, the chief executive officer now owns 808,675 shares in the company, valued at approximately $37,845,990. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.
Shares of Atara Biotherapeutics Inc (NASDAQ:ATRA) traded up $3.30 during mid-day trading on Wednesday, reaching $48.35. The company had a trading volume of 1,427,869 shares, compared to its average volume of 1,256,386. The firm has a market cap of $1,480.00, a PE ratio of -13.93 and a beta of 2.71. Atara Biotherapeutics Inc has a 1 year low of $11.80 and a 1 year high of $49.90.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ATRA. SG Americas Securities LLC acquired a new position in Atara Biotherapeutics during the 3rd quarter worth approximately $142,000. Voya Investment Management LLC increased its position in Atara Biotherapeutics by 16.2% during the 2nd quarter. Voya Investment Management LLC now owns 11,813 shares of the biotechnology company’s stock worth $165,000 after purchasing an additional 1,651 shares during the period. Russell Investments Group Ltd. acquired a new position in Atara Biotherapeutics during the 3rd quarter worth approximately $170,000. The Manufacturers Life Insurance Company increased its position in Atara Biotherapeutics by 7.2% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 20,377 shares of the biotechnology company’s stock worth $285,000 after purchasing an additional 1,369 shares during the period. Finally, Dimensional Fund Advisors LP increased its position in Atara Biotherapeutics by 2.9% during the 2nd quarter. Dimensional Fund Advisors LP now owns 21,718 shares of the biotechnology company’s stock worth $304,000 after purchasing an additional 610 shares during the period. Institutional investors own 69.58% of the company’s stock.
About Atara Biotherapeutics
Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells.
Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.